Toborzás még nem indult1/2. fázis
Gene Therapy Trial for OTOF-mediated Hearing Loss
A legfontosabb adatok
- Ki végzi
- Akouos Inc.
- Hol
- Spanyolország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- EU 2023-505128-76-00
- NCT05821959
- Állapot
- Toborzás még nem indult
- Fázis
- 1/2. fázis
- Résztvevők
- 2 fő, tervezett
- Kezdés
- 2023. okt. 1.
- Várható befejezés
- 2028. ápr. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2023. október 5.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for children and teenagers with profound hearing loss in both ears caused by changes in both copies of the OTOF gene. It tests a gene therapy called AAVAnc80-hOTOF.
- Életkor
- 7 to 17 years for Cohort #1a; 2 to 17 years for Cohorts #1b and #2.
- Nem
- All sexes can join.
- A betegség stádiuma
- Profound sensorineural hearing loss (inner ear or nerve hearing loss) in both ears, shown by an ABR hearing test. The study ear must still have working OAEs (a sound test of inner ear cells).
- Korábbi kezelés
- No middle or inner ear surgery in the study ear in the last 6 months, except ear tubes or eardrum fluid drainage. No investigational drug trial in the last 6 months. No gene therapy trial ever.
- Biomarker vagy leletérték
- Changes (mutations) in both copies of the OTOF gene, confirmed by a certified genetic test.
A részvétel fő kizáró okai
- Health problems that make surgery, general anaesthesia or gene therapy unsafe, such as serious liver, kidney, lung or blood problems.
- Inner ear malformations seen on MRI, or ear shapes that block the surgery.
- Word recognition score above 30% with a hearing aid in either ear, without a cochlear implant.
- Cochlear implants in both ears, or long-term middle ear infection or eardrum hole in the study ear.
- Being pregnant or breastfeeding, or not willing to use effective birth control for 1 year.
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Age seven to 17 years old (inclusive) for Cohort #1a; age two to 17 years old (inclusive) at the time of AAVAnc80-hOTOF administration for Cohorts #1b and #2
- Biallelic mutations in the OTOF gene confirmed by: 1) a European Conformity (CE)-marked genetic test for OTOF, including as part of a clinical panel for hearing loss/deafness genes; or 2) a Clinical Laboratory Improvements Amendment (CLIA)-certified or equivalent laboratory’s genetic test for OTOF, including as part of a clinical panel for hearing loss/deafness genes
- Clinical presentation of Profound bilateral sensorineural hearing loss as assessed by ABR threshold OR absent or abnormal diagnostic ABR (i.e., no click-evoked ABR for levels up to and including 90 dB nHL, consistent with diagnosis of Profound bilateral sensorineural hearing loss); when afebrile
- Preserved OAEs (distortion product OAEs [DPOAEs]), defined as more than one frequency within normal response limits in the speech frequency range, in the study ear
- Participants of child-bearing potential (males and females) agree to use effective contraceptive methods for one year after administration of AAVAnc80-hOTOF. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials as described in the corresponding Informed Consent Form (ICF). • Females of child-bearing potential include those who have experienced menarche. • Males who have reached sexual maturity are considered to be of child-producing potential unless they have had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy
- Legally authorized representative and/or participant willingness to comply with all trial requirements, as evidenced by successful completion of the informed consent process and participant assent process (where appropriate)
- Legally authorized representative and/or participant willingness to participate in separate LTFU protocol after completion of this trial
Ki nem vehet részt
- Prior middle or inner ear surgery in the study ear, with the exception of tympanostomy tubes or tympanocentesis, within six months prior to administration (Day 0)
- Known sensitivity or contraindications to medications planned for use in the peri-operative period, including corticosteroids
- Prior participation in a clinical trial with an investigational drug, within six months prior to administration (Day 0), or any prior participation in a gene therapy clinical trial
- Anatomic abnormalities of the ear that preclude the surgical approach, e.g., canal atresia
- Congenital malformations of the inner ear, as confirmed by non-contrast, high-definition magnetic resonance imaging (MRI), including but not limited to: cochlear malformations (e.g., Mondini malformation); cochlear nerve dysplasia; congenital atresia; absence of round and oval windows; Scheibe dysplasia; membranous labyrinth; Large Vestibular Aqueduct; and anomalies of the eustachian tube and accessory structures. Note: historic MRI data OR historic computed tomography (CT) data (high resolution, no contrast) obtained prior to enrollment are acceptable, provided the studies are adequate to assess inner ear morphology. A CT scan may be obtained at the discretion of the surgeon to further evaluate the bony anatomy, if the MRI and/or historic imaging studies are indeterminate
- Hearing loss attributed mainly to past ototoxic exposures (e.g., severe prematurity, hypoxia, ototoxic medication such as chemotherapy)
- Bilateral cochlear implants
- Word recognition score (for individuals capable of performing the assessment) as follows: > 30% in the best aided condition in the study ear or > 30% in the best aided (hearing aid) condition in the contralateral ear, without cochlear implant use
- Any other condition that would not allow the potential participant to complete follow-up examinations during the course of the trial and/or, in the opinion of the Investigator, makes the potential participant unsuitable for the trial
- Chronic otitis media or chronic eardrum perforation in the study ear
- Medical or psychological conditions that contraindicate undergoing surgery, general anaesthesia, and/or investigational gene therapy administration, including: a) Recurrent or persistent hypertension with systolic and/or diastolic blood pressure (BP) more than 10mm Hg above the 90th percentile for age b) Recurrent or persistent hepatic dysfunction indicated by bilirubin > 1.5X the upper limit of normal (ULN) for age, AST > 2X the ULN for age, or ALT > 2X the ULN for age c) Renal glomerular dysfunction requiring treatment, including diuretics and/or dialysis; or estimated glomerular filtration rate (GFR) < 60mL/min/1.73m2 d) Recurrent or persistent pulmonary dysfunction that requires intermittent supplemental oxygen or persistent oxygen saturation less than 95% on room air (at rest) e) Recurrent or persistent hemoglobin < 10 g/dL (or equivalent) f) Recurrent or persistent platelet count of < 100,000/mL g) Other applicable conditions
- Individuals of childbearing potential who are pregnant and/or breastfeeding or unwilling to use effective contraception for one year following AAVAnc80-hOTOF administration
- Unwillingness or inability of the potential participant (and legally authorized representative, if participant is a minor) to comply with all investigational requirements and follow up
- Evidence of persistent middle ear dysfunction, as demonstrated by repeated abnormal tympanometry (an immittance measure of middle ear function). Note: in the presence of tympanostomy tubes, large volume tympanograms are not exclusionary
- Clinical history consistent with endolymphatic hydrops (documented fluctuating sensorineural hearing loss in the affected ear and/or episodic vertigo attributable to the study ear)
- Evidence of patent cochlear aqueduct
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objective of Part A is to assess the safety, tolerability, and bioactivity of escalating doses of AAVAnc80-hOTOF.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 1/2 Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss due to Biallelic Otoferlin Gene (OTOF) Mutations
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2023. október 5.